Gilead Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative healthcare since its founding in 1987. With a strong presence in regions such as Europe and Asia, Gilead focuses on the research, development, and commercialisation of antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. The company is renowned for its groundbreaking therapies, including Biktarvy and Harvoni, which have transformed the treatment landscape for chronic viral infections. Gilead's commitment to advancing medicine is underscored by its significant achievements, including multiple FDA approvals and a robust pipeline of investigational therapies. As a key player in the biopharmaceutical industry, Gilead Sciences continues to shape the future of healthcare through its dedication to scientific innovation and patient care.
How does Gilead Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Gilead Sciences's score of 58 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Gilead Sciences reported total greenhouse gas (GHG) emissions of approximately 1,186,000,000 kg CO2e. This includes Scope 1 emissions of about 56,096,000 kg CO2e, Scope 2 emissions of approximately 22,339,000 kg CO2e, and significant Scope 3 emissions totalling around 1,121,798,000 kg CO2e. Gilead has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 GHG emissions by 46% by 2030, using a 2019 baseline. Additionally, the company is committed to reducing its Scope 3 emissions by 15% over the same timeframe. Gilead's near-term targets align with the Science Based Targets initiative (SBTi) and are consistent with the reductions necessary to limit global warming to 1.5°C. Furthermore, Gilead aims to achieve carbon net-zero operational GHG emissions by 2030, reinforcing its commitment to sustainability and environmental responsibility. The company’s strategy focuses on significant reductions in both direct emissions (Scope 1) and emissions from purchased energy (Scope 2), with a target of 25% reduction by 2025 compared to a 2016 baseline. These initiatives reflect Gilead's proactive approach to addressing climate change and its impact on the pharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|
Scope 1 | 44,754,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 36,813,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gilead Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.